Towards epigenetic regulation of triple-negative breast cancer via ligand-mediated nanoparticles

References

• 1. Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021).
  MedlineGoogle Scholar
• 2. Waks AG, Winer EP. Breast cancer treatment: a review. JAMA 321(3), 288–300 (2019).
  Medline CASGoogle Scholar
• 3. Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res. Treat. 115(2), 423–428 (2009).
  MedlineGoogle Scholar
• 4. Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat. Rev. Clin. Oncol. 13(11), 674–690 (2016).
  Medline CASGoogle Scholar
• 5. Romagnolo DF, Daniels KD, Grunwald JT, Ramos SA, Propper CR, Selmin OI. Epigenetics of breast cancer: modifying role of environmental and bioactive food compounds. Mol. Nutr. Food Res. 60(6), 1310–1329 (2016).
  Medline CASGoogle Scholar
• 6. Sun Y-S, Zhao Z, Yang Z-N et al. Risk factors and preventions of breast cancer. Int. J. Biol. Scie. 13(11), 1387 (2017).
  Medline CASGoogle Scholar
• 7. Garcia-Martinez L, Zhang Y, Nakata Y, Chan HL, Morey L. Epigenetic mechanisms in breast cancer therapy and resistance. Nat. Commun. 12(1), 1–14 (2021).
  MedlineGoogle Scholar
• 8. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet 3(6), 415–428 (2002).
  Medline CASGoogle Scholar
• 9. Temian DC, Pop LA, Irimie AI, Berindan-Neagoe I. The epigenetics of triple-negative and basal-like breast cancer: current knowledge. J. Breast Cancer 21(3), 233–243 (2018).
  MedlineGoogle Scholar
• 10. Esteller M. Epigenetics in cancer. N. Engl. J. Med. 358(11), 1148–1159 (2008).
  Medline CASGoogle Scholar
• 11. Martínez-Galán J, Torres-Torres B, Núñez MI et al. ESR1gene promoter region methylation in free circulating DNA and its correlation with estrogen receptor protein expression in tumor tissue in breast cancer patients. BMC Cancer 14(1), 1–8 (2014).
  MedlineGoogle Scholar
• 12. Lombaerts M, Van Wezel T, Philippo K et al. E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines. Br. J. Cancer 94(5), 661 (2006).
  Medline CASGoogle Scholar
• 13. Silverman LR. DNA methyltransferase inhibitors in myelodysplastic syndrome. Best Pract. Res. Clin. Haematol. 17(4), 585–594 (2004).
  Medline CASGoogle Scholar
• 14. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell 20(1), 85–93 (1980).
  Medline CASGoogle Scholar
• 15. Wijermans P, Lubbert M, Verhoef G et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J. Clin. Oncol. 18(5), 956–956 (2000).
  Medline CASGoogle Scholar
• 16. Kantarjian H, Oki Y, Garcia-Manero G et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109(1), 52–57 (2007).
  Medline CASGoogle Scholar
• 17. Momparler RL, Bouffard DY, Momparler LF, Dionne J, Bélanger K, Ayoub J. Pilot phase I–II study on 5-aza-2′-deoxycytidine (decitabine) in patients with metastatic lung cancer. Anticancer Drugs 8(4), 358–368 (1997).
  Medline CASGoogle Scholar
• 18. Appleton K, Mackay HJ, Judson I et al. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J. Clin. Oncol. 25(29), 4603–4609 (2007).
  Medline CASGoogle Scholar
• 19. Karahoca M, Momparler RL. Pharmacokinetic and pharmacodynamic analysis of 5-aza-2′-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy. Clin. Epigenetics 5(1), 3 (2013).
  Medline CASGoogle Scholar
• 20. Yu J, Qin B, Moyer AM et al. DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. J. Clin. Invest. 128(6), 2376–2388 (2018).
  Google Scholar
• 21. Naz A, Cui Y, Collins CJ, Thompson DH, Irudayaraj J. PLGA-PEG nano-delivery system for epigenetic therapy. Biomed. Pharmacother. 90, 586–597 (2017).
  Medline CASGoogle Scholar
• 22. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Rel. 65(1–2), 271–284 (2000).
  Medline CASGoogle Scholar
• 23. Picheth GF, Ganzella FA, Filizzola JO et al. Ligand-mediated nanomedicines against breast cancer: a review. Nanomedicine 17(9), 645–664 (2022).
  CASGoogle Scholar
• 24. Li S-Y, Sun R, Wang H-X et al. Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells. J. Control. Rel. 205, 7–14 (2015).
  Medline CASGoogle Scholar
• 25. Oshi M, Gandhi S, Tokumaru Y et al. Conflicting roles of EGFR expression by subtypes in breast cancer. Am. J. Cancer Res. 11(10), 5094 (2021).
  Medline CASGoogle Scholar
• 26. Park HS, Jang MH, Kim EJ et al. High EGFR gene copy number predicts poor outcome in triple-negative breast cancer. Mod. Pathol. 27(9), 1212–1222 (2014).
  Medline CASGoogle Scholar
• 27. Gumuskaya B, Alper M, Hucumenoglu S, Altundag K, Uner A, Guler G. EGFR expression and gene copy number in triple-negative breast carcinoma. Cancer Genet. Cytogenet. 203(2), 222–229 (2010).
  Medline CASGoogle Scholar
• 28. Singh A, Naskar AK, Haynes D, Drews MJ, Smith DW. Synthesis, characterization and surface properties of poly(lactic acid)-perfluoropolyether block copolymers. Polym. Int. 60(3), 507–516 (2011).
  CASGoogle Scholar
• 29. Giuntoli G, Rosi L, Frediani M, Sacchi B, Frediani P. Fluoro-functionalized PLA polymers as potential water-repellent coating materials for protection of stone. J. Appl. Polym. Sci. 125(4), 3125–3133 (2012).
  CASGoogle Scholar
• 30. Diou O, Fattal E, Delplace V et al. RGD decoration of PEGylated polyester nanocapsules of perfluorooctyl bromide for tumor imaging: influence of pre or post-functionalization on capsule morphology. Eur. J. Pharm. Biopharm. 87(1), 170–177 (2014).
  Medline CASGoogle Scholar
• 31. Diou O, Tsapis N, Giraudeau C et al. Long-circulating perfluorooctyl bromide nanocapsules for tumor imaging by 19 FMRI. Biomaterials 33(22), 5593–5602 (2012).
  Medline CASGoogle Scholar
• 32. Gupta SK, Sachan N, Chandra P, Sharma AK. Application of RP-HPLC method for stability study and quantifying decitabine in bulk drug and in pharmaceutical dosage form. International Journal of Pharmaceutical Research 12(4), 261–267 (2020).
  CASGoogle Scholar
• 33. Gerlier D, Thomasset N. Use of MTT colorimetric assay to measure cell activation. J. Immunol. Methods 94(1-2), 57–63 (1986).
  Medline CASGoogle Scholar
• 34. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2^-ΔΔCt method. Methods 25(4), 402–408 (2001).
  Medline CASGoogle Scholar
• 35. Picheth G, Houvenagel S, Dejean C et al. Echogenicity enhancement by end-fluorinated polylactide perfluorohexane nanocapsules: towards ultrasound-activable nanosystems. Acta Biomaterialia 64, 313–322 (2017).
  Medline CASGoogle Scholar
• 36. Mahou R, Wandrey C. Versatile route to synthesize heterobifunctional poly (ethylene glycol) of variable functionality for subsequent pegylation. Polymers 4(1), 561–589 (2012).
  Google Scholar
• 37. Houvenagel S, Picheth G, Dejean C et al. End-chain fluorination of polyesters favors perfluorooctyl bromide encapsulation into echogenic PEGylated nanocapsules. Polym. Chem. 8(16), 2559–2570 (2017).
  CASGoogle Scholar
• 38. Lee J-J, Kang JA, Ryu Y et al. Genetically engineered and self-assembled oncolytic protein nanoparticles for targeted cancer therapy. Biomaterials 120, 22–31 (2017).
  Medline CASGoogle Scholar
• 39. Kohda D, Inagaki F. Complete sequence-specific ¹H nuclear magnetic resonance assignments for mouse epidermal growth factor. J. Biochem. 103(3), 554–571 (1988).
  Medline CASGoogle Scholar
• 40. Leff DV, Brandt L, Heath JR. Synthesis and characterization of hydrophobic, organically-soluble gold nanocrystals functionalized with primary amines. Langmuir 12(20), 4723–4730 (1996).
  CASGoogle Scholar
• 41. Kumar A, Mandal S, Selvakannan P, Pasricha R, Mandale A, Sastry M. Investigation into the interaction between surface-bound alkylamines and gold nanoparticles. Langmuir 19(15), 6277–6282 (2003).
  Medline CASGoogle Scholar
• 42. Jaworska A, Jablonska A, Wilanowski T, Palys B, Sek S, Kudelski A. Influence of amine and thiol modifications at the 3′ ends of single stranded DNA molecules on their adsorption on gold surface and the efficiency of their hybridization. Spectrochim. Acta A Mol. Biomol. Spectrosc. 203, 31–39 (2018).
  Medline CASGoogle Scholar
• 43. Wang DK, Varanasi S, Fredericks PM et al. FT-IR characterization and hydrolysis of PLA-PEG-PLA based copolyester hydrogels with short PLA segments and a cytocompatibility study. J. Polym. Sci. Part A: Polymer Chemistry 51(24), 5163–5176 (2013).
  CASGoogle Scholar
• 44. Kaminski GA, Sierakowski MR, Pontarolo R, dos Santos LA, de Freitas RA. Layer-by-layer polysaccharide-coated liposomes for sustained delivery of epidermal growth factor. Carbohydr. Polym. 140, 129–135 (2016).
  Medline CASGoogle Scholar
• 45. Kim S-E, Lee PW, Pokorski JK. Biologically triggered delivery of EGF from polymer fiber patches. ACS Macro Lett. 6(6), 593–597 (2017).
  Medline CASGoogle Scholar
• 46. Klenkler BJ, Griffith M, Becerril C, West-Mays JA, Sheardown H. EGF-grafted PDMS surfaces in artificial cornea applications. Biomaterials 26(35), 7286–7296 (2005).
  Medline CASGoogle Scholar
• 47. Yamamoto S, Iwamaru Y, Shimizu Y et al. Epidermal growth factor-nanoparticle conjugates change the activity from anti-apoptotic to pro-apoptotic at membrane rafts. Acta Biomaterialia 88, 383–391 (2019).
  Medline CASGoogle Scholar
• 48. Khanehzar A, Fraire JC, Xi M et al. Nanoparticle–cell interactions induced apoptosis: a case study with nanoconjugated epidermal growth factor. Nanoscale 10(14), 6712–6723 (2018).
  Medline CASGoogle Scholar
• 49. Nguyen PV, Allard-Vannier E, Chourpa I, Hervé-Aubert K. Nanomedicines functionalized with anti-EGFR ligands for active targeting in cancer therapy: biological strategy, design and quality control. Int. J. Pharm. 605, 120795 (2021).
  Medline CASGoogle Scholar
• 50. Lei C, Wang Y, Huang Y et al. Up-regulated miR155 reverses the epithelial–mesenchymal transition induced by EGF and increases chemo-sensitivity to cisplatin in human CaSki cervical cancer cells. PLoS ONE 7(12), e52310 (2012).
  Medline CASGoogle Scholar
• 51. Rusnak D, Alligood K, Mullin R et al. Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb^®, GW572016) in an expanded panel of human normal and tumour cell lines. Cell Prolif. 40(4), 580–594 (2007).
  Medline CASGoogle Scholar
• 52. Dai X, Cheng H, Bai Z, Li J. Breast cancer cell line classification and its relevance with breast tumor subtyping. J. Cancer 8(16), 3131 (2017).
  MedlineGoogle Scholar
• 53. Seniski GG, Camargo AA, Ierardi DF et al. ADAM33 gene silencing by promoter hypermethylation as a molecular marker in breast invasive lobular carcinoma. BMC Cancer 9(1), 1–10 (2009).
  MedlineGoogle Scholar
• 54. Chequin A, Costa LE, De Campos FF et al. Antitumoral activity of liraglutide, a new DNMT inhibitor in breast cancer cells in vitro and in vivo. Chem. Biol. Interact. 349, 109641 (2021).
  Medline CASGoogle Scholar
• 55. Paz MF, Fraga MF, Avila S et al. A systematic profile of DNA methylation in human cancer cell lines. Cancer Res. 63(5), 1114–1121 (2003).
  Medline CASGoogle Scholar
• 56. Romero-Garcia S, Prado-Garcia H, Carlos-Reyes A. Role of DNA methylation in the resistance to therapy in solid tumors. Front. Oncol. 10, 1152 (2020).
  MedlineGoogle Scholar
• 57. Villanueva L, Álvarez-Errico D, Esteller M. The contribution of epigenetics to cancer immunotherapy. Trends Immunol. 41(8), 676–691 (2020).
  Medline CASGoogle Scholar
• 58. Nepali K, Liou J-P. Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends. J. Biomed. Sci. 28(1), 1–58 (2021).
  MedlineGoogle Scholar